N/A
Manufactured by Viatris Specialty LLC
3,510 FDA adverse event reports analyzed
Last updated: 2026-04-15
FELBAMATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Viatris Specialty LLC. The most commonly reported adverse reactions for FELBAMATE include SEIZURE, DRUG INEFFECTIVE, CONVULSION, OFF LABEL USE, SOMNOLENCE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FELBAMATE.
Out of 1,714 classified reports for FELBAMATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 3,510 FDA FAERS reports that mention FELBAMATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include SEIZURE, DRUG INEFFECTIVE, CONVULSION, OFF LABEL USE, SOMNOLENCE, CONDITION AGGRAVATED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Viatris Specialty LLC in connection with FELBAMATE. Always verify the specific product and NDC with your pharmacist.